Additional file 1 of Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy
收藏数据链接：
官方服务：
资源简介：
Additional file 1: Supplementary Table 1. Treatment history and strategies for patients who achieved a long duration of intracranial response after furmonertinib 160mg with or without anti-angiogenic agent as salvage therapy.
创建时间：
2024-08-13
